Quality of life in patients who underwent low-dose-rate brachytherapy for prostate cancer with 10-year follow-up
Brachytherapy · 2026
DOI: 10.1016/j.brachy.2026.07.164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Yasushi Nakai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Quality of Life. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the long-term follow-up quality of life (QOL) outcomes in patients who underwent low-dose-rate brachytherapy (LDR-BT) for prostate cancer. METHODS AND MATERIALS: Between May 2010 and January 2018, 853 patients who completed Expanded Prostate Cancer Index Composite (EPIC) questionnaires before treatment were enrolled in the present study. QOL was evaluated before treatments, at 1, 3, 6, 12, 24, 36, 48, 60, and 120 months after LDR-BT. Factors related to satisfaction with LDR-BT were evaluated using binary logistic regression analysis. RESULTS: At 1, 3, 6, 12, 24, 36, 48, 60 and 120 months after LDR-BT, 553/852 (65%), 570/840 (68%), 609/847 (72%), 677/837 (81%), 645/814 (79%), 636/789 (81%), 656/767 (86%), 626/730 (86%), and 282/330 (85%) patients were satisfied with the treatment. At 24, 60, and 120 months after LDR-BT, maintained QOL in the urinary (Odds ratio (OR): 0.43, 95% confidence interval (CI): 0.29-0.61) and bowel (OR: 0.61, 95% CI 0.43-0.87) domains, maintained QOL in the urinary (OR: 0.30, 95% CI 0.20-0.47), bowel (OR: 0.53, 95% CI 0.35-0.82), and hormonal domains (OR: 0.44, 95% CI 0.28-0.70), and biochemical recurrence-free within 5 years after LDR-BT (OR: 0.16, 95% CI 0.07-0.39), and maintained QOL in the bowel (OR: 0.43, 95% CI 0.23-0.81) domain were significantly related to satisfaction with LDR-BT for prostate cancer, respectively. CONCLUSIONS: Maintained urinary, bowel, and hormonal QOL and biochemical control were related to satisfaction with LDR-BT for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan.
- Department of Urology, Nara Medical University, Nara, Japan.
- Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan; Department of Radiation Oncology, Nara Medical University, Nara, Japan.
- Department of Radiation Oncology, Nara Medical University, Nara, Japan.
- Department of Diagnostic Pathology, Nara Medical University, Nara, Japan.
- Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan. Electronic address: sendo@naramed-u.ac.jp.
Zitieren
APA
Nakai, Y., Onishi, K., Asakawa, I., Miyake, M., Yamaki, K., Isohashi, F., Yoshizawa, A., Fujimoto, K., & Tanaka, N. (2026). Quality of life in patients who underwent low-dose-rate brachytherapy for prostate cancer with 10-year follow-up. Brachytherapy. https://doi.org/10.1016/j.brachy.2026.07.164
Vancouver
Nakai Y, Onishi K, Asakawa I, Miyake M, Yamaki K, Isohashi F, et al. Quality of life in patients who underwent low-dose-rate brachytherapy for prostate cancer with 10-year follow-up. Brachytherapy. 2026. doi:10.1016/j.brachy.2026.07.164
BibTeX
@article{Nakai2026,
author = {Nakai, Yasushi and Onishi, Kenta and Asakawa, Isao and Miyake, Makito and Yamaki, Kaori and Isohashi, Fumiaki and Yoshizawa, Akihiko and Fujimoto, Kiyohide and Tanaka, Nobumichi},
title = {Quality of life in patients who underwent low-dose-rate brachytherapy for prostate cancer with 10-year follow-up},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2026.07.164}
}
EUVIMED